Trial
NCT03763175
Efficacy and Safety of SYN-010 in IBS-C
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Cedars-Sinai Medical Center
Collaborators
Theriva Biologics, Inc.
Condition
Irritable Bowel Syndrome With Constipation
Intervention
SYN-010 21 mg
Why stopped
Interim Futility Analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-07-13